| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | For oral administration |
|
Still deciding? Get samples of US$ 0/BOX
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Indications:
For the treatment of chloroquine resistant falciparum malaria in adults and children aged 5 years or older (and ≥ 20kg)
Dosage and administration:
Posology
Treatment of chloroquine resistant falciparum malaria
Adults (including the elderly) and children aged 12 years and over: 600mg of quinine sulfate given every 8 hours for 7 days. The dose may depend upon the size of the patient, severity of infection, and evidence of renal or liver disease (when the intervals should be increased), due to a prolonged half-life of the drug.
Paediatric population
Treatment of chloroquine resistant falciparum malaria
The dosage regimen for children by mouth is 10mg of quinine sulfate per kg body weight given every 8 hours for 7 days. Quinine sulfate 200mg tablets are not suitable for children weighing less than 20kg or less than 5 years old.
Method of administration
For oral administration.
Contraindications:
- Hypersensitivity to the active substance or to any of the excipients
- Tinnitus
- Optic neuritis
- Haemoglobinuria
- Myasthenia gravis (quinine may cause severe respiratory distress and dysphagia in these patients)
Precautions:
Chinchonism
Administration of quinine may give rise to cinchonism, which is generally more severe in overdose, but may also occur in normal therapeutic doses.
Hypersensitivity
Hypersensitivity to quinine may also occur with symptoms of cinchonism together with urticaria, flushing, pruritus, rash, fever, angioedema, dyspnoea and asthma.
Cardiac disorders
Quinine should be used with caution in patients with atrial fibrillation, conduction defects and heart block or other serious heart disease.
Glucose-6-Phosphate Dehydrogenase (G-6-PD) Deficiency
The administration of quinine to a patient who has previously been suffering from a chronic and inadequately controlled malarial infection may precipitate an attack of Blackwater fever.
Quinine should not be withheld from pregnant women who have life threatening malaria.
Treatment should be monitored in all patients in case signs of resistance develop.
Thrombocytopenia
Quinine may cause unpredictable serious and life-threatening thrombocytopenia, which is thought to be an idiosyncratic hypersensitivity reaction.
Storage:
Do not store above 25°C.
){kind=link}